Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Oct;16(10):1803-1814.
doi: 10.1111/cts.13583. Epub 2023 Aug 29.

Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study

Yangfeng Ding  1 , Wei Li  2 , Xin Guan  3 , Na Liu  4 , Ying Zhou  5 , Gaojie Li  2 , Xiaohua Wang  6 , Zhidong Wang  7 , Xiao Xiao  7 , Bin Yang  6 , Chengzhi Lv  5 , Chunlei Zhang  3 , Yuling Shi  1
Affiliations
Multicenter Study

Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study

Yangfeng Ding et al. Clin Transl Sci. 2023 Oct.

Abstract

Secukinumab is effective in treating patients with moderate-to-severe plaque psoriasis. However, most studies assessing its effectiveness in routine clinical settings in China are mostly single-center studies with a limited sample size. The objective of this study was to assess secukinumab's efficacy, treatment patterns, and characteristics in patients with moderate-to-severe plaque psoriasis. This 24-week, multicenter (n = 5) retrospective study analyzed the data of Chinese adult patients with moderate-to-severe plaque psoriasis who initiated secukinumab treatment between May 2019 and March 2020. The Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator's Global Assessment Modified 2011 (IGA mod 2011), and Dermatology Life Quality Index (DLQI) were assessed. Dermatologists documented the treatment dosage and modification reasons. Of the 244 secukinumab-naïve patients, most were men (73.4%, 179/244) and weighed 60-90 kg (72.8%, 177/243). The mean (SD) age at secukinumab initiation was 38.1 (11.6) years, and the disease duration was 13.5 (7.9) years. Most patients (97.1%, 237/244) received secukinumab 300 mg. At weeks 4, 12, 16, and 24, the proportion of patients achieving PASI 75 (≥75% reduction from baseline) was 40.0%, 92.1%, 88.4%, and 88.9%, respectively; PASI 90 was 15.0%, 73.7%, 81.4%, and 68.3%, respectively; and PASI 100 was 8.7%, 40.8%, 58.1%, and 41.3%, respectively. During the same periods, BSA and IGA mod 2011 showed similar improvement trends. An increasing proportion of patients achieved DLQI of 0-1 (21.6%, 65.7%, 75.0%, and 80.3%, respectively). Treatment modification was highest at week 12. The average interval between two administrations after week 4 was 62.95 days. Secukinumab was highly effective in improving the PASI, IGA, BSA, and DLQI in Chinese patients with moderate-to-severe plaque psoriasis throughout the first 24 weeks. The treatment pattern for Chinese patients differs from that in the clinical guidelines.

PubMed Disclaimer

Conflict of interest statement

Yuling Shi, Chunlei Zhang, Chengzhi Lv, Bin Yang, Dingfeng Yang, Wei Li, Xin Guan, Na Liu, Ying Zhou, Gaojie Li, and Xiaohua Wang received support from Novartis in terms of funding, provision of study materials, operational and medical support, and medical writing. Zhidong Wang and Xiao Xiao are Novartis employees, who supported the investigators through funding, study materials, operational and medical support, and medical writing. All other authors declared no competing interests regarding this work.

Figures

FIGURE 1
FIGURE 1
Absolute change in PASI score from baseline. PASI, Psoriasis Area and Severity Index.
FIGURE 2
FIGURE 2
Proportion of patients achieved PASI 75, 90, 100 in all patients. PASI, Psoriasis Area and Severity Index.
FIGURE 3
FIGURE 3
Proportion of patients achieved body surface area less than or equal to 3%.
FIGURE 4
FIGURE 4
Proportion of patients achieved IGA mod 2011 (0‐1). IGA mod 2011, Investigator's Global Assessment Modified 2011.
FIGURE 5
FIGURE 5
Proportion of patients achieved DLQI (0‐1). DLQI, Dermatology Life Quality Index.
See this image and copyright information in PMC

References

    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945‐1960. doi: 10.1001/jama.2020.4006 - DOI - PubMed
    1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient‐membership survey. Arch Dermatol. 2001;137:280‐284. - PubMed
    1. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383‐392. doi: 10.2165/00128071-200506060-00005 - DOI - PubMed
    1. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982‐986. doi: 10.1016/0190-9622(95)91336-x - DOI - PubMed
    1. Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate‐to‐severe plaque psoriasis: a multi‐center, retrospective, real‐life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18:727‐735. doi: 10.1080/14712598.2018.1481503 - DOI - PubMed

Publication types